IMAB 241115 7.50P (IMAB241115P7500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

IMAB241115P7500

Watchlist

0.00
0.000.00%

15min DelayTrading Nov 7 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

i-mab (IMAB.US) appoints Sean Fu as the company's Chief Executive Officer.
i-mab (IMAB.US) announced today that Dr. Sean (Xi-Yong) Fu, PhD, MBA, has been officially appointed as the Chief Executive Officer ("CEO") of the company, effective November 1, 2024. Dr. Fu has been serving as the interim CEO since July 15, 2024, and will continue as a member of the board of directors of I-Mab.
Gelonghui FinanceNov 6 08:31 ET
Express News | I-Mab - Appoints Sean Fu as CEO
ReutersNov 6 07:00 ET
Express News | I-Mab Appoints Sean Fu, Phd, MBA, as Chief Executive Officer
ReutersNov 6 07:00 ET
Express News | U.S.-Listed Shares of Chinese Firms Drop Premarket on Worries Over Growing U.S.-China Trade Tensions Under Trump Presidency
ReutersNov 6 04:27 ET
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
I-Mab BiopharmaNov 6 00:00 ET
Express News | I-Mab - on Nov 1 Federal Jury Found in Favor of Defendants in Bifurcated Trial Relating to Some of Co's Trade Secret Information
ReutersNov 5 16:02 ET

Comments

Teddy123

Oct 30 06:16

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

$I-Mab (IMAB.US)$
ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18....

Update

$I-Mab (IMAB.US)$ Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
Benzinga· 1 min ago
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels.The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; giv...

Jaguar8

Sep 10 06:55

NEWS

$I-Mab (IMAB.US)$
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials
- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients
- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to ...

Moomoo Breakfast US

Sep 12, 2022 07:36

Columns Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%,...